Get In Touch

Acute Graft Versus Host Disease (GvHD) Treatment Market to Reach Valuation of US$ 634.3 Mn by 2031: Transparency Market Research

Acute Graft Versus Host Disease (GvHD) Treatment Market: Introduction

According to the report, the global acute graft versus host disease (GvHD) treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031. The rise in focus on introducing novel effective therapeutics to address the unmet medical needs is anticipated to drive the global acute graft versus host disease (GvHD) treatment market from 2021 to 2031. North America is expected to account for significant share of the global acute graft versus host disease (GvHD) treatment market during the forecast period. The growth of the acute graft versus host disease (GvHD) treatment market in the region can be attributed to the presence of key players and rise in access to health care due to well-established healthcare infrastructure.

The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Emerging approached for mesenchymal stem cells (MSCs) to treat acute graft versus host disease (GvHD) in Japan is projected to boost the growth of market in the region.

Focus on Research & Development to Propel Market

The development of innovative and effective health products for humans has increased in the past few decades. Key players focus on introduction of new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market. For instance, in July 2021, Equillium, Inc. announced the completion of an end-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) for use of itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD).

Corticosteroids to Dominate Global Market

In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others. First-line use of corticosteroids in the treatment of GvHD is likely to boost the growth of segment.

Intravenous Segment to Expand at High Growth Rate

Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous. Increase in usage and launch of new injectable drugs for treatment of acute graft versus host disease are projected to augment the segment during the forecast period.

Retail Pharmacies to Account for Major Share of Global Market

In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The increase in the number of different doses and medications for the treatment of acute GvHD is anticipated to drive the retail pharmacies segment.

Competition Landscape of Acute Graft Versus Host Disease (GvHD) Treatment Market

The report provides profiles of leading players operating in the global acute graft versus host disease (GvHD) treatment market. These include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited.

Global Acute Graft Versus Host Disease (GvHD) Treatment Market: Segmentation

  • Acute Graft Versus Host Disease (GvHD) Treatment Market, by Drug Class
    • Corticosteroids
    • Immunosuppressive Agents
    • Biological Therapy
    • Kinase Inhibitors
    • Monoclonal Antibody
    • Mesenchymal Stem Cell (MSC)
    • Others
  • Acute Graft Versus Host Disease (GvHD) Treatment Market, by Route of Administration
    • Oral
    • Topical
    • Intravenous
  • Acute Graft Versus Host Disease (GvHD) Treatment Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Acute Graft Versus Host Disease (GvHD) Treatment Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of the Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com/

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC